New Zealand markets closed

Kyverna Therapeutics, Inc. (KYTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.43-0.90 (-6.75%)
At close: 04:00PM EDT
12.43 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 535.92M
Enterprise value 176.97M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.48
Enterprise value/revenue 3.34k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-58.70%
S&P500 52-week change 325.26%
52-week high 330.60
52-week low 312.16
50-day moving average 319.73
200-day moving average 322.53

Share statistics

Avg vol (3-month) 3384.73k
Avg vol (10-day) 3302.46k
Shares outstanding 543.12M
Implied shares outstanding 643.12M
Float 822.57M
% held by insiders 110.73%
% held by institutions 151.57%
Shares short (30 Apr 2024) 41.94M
Short ratio (30 Apr 2024) 44.37
Short % of float (30 Apr 2024) 48.15%
Short % of shares outstanding (30 Apr 2024) 44.50%
Shares short (prior month 28 Mar 2024) 41.45M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-54.89%
Return on equity (ttm)-125.95%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -60.7M
Net income avi to common (ttm)-60.37M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)57.54M
Total cash per share (mrq)1.34
Total debt (mrq)9.08M
Total debt/equity (mrq)18.46%
Current ratio (mrq)3.06
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-52.41M
Levered free cash flow (ttm)-29.74M